BioWorld

May 20, 2009

Elixir Inks $500M Novartis Option Deal and Closes $12M Financing

Elixir Pharmaceuticals Inc. signed a potential $500 million deal giving Novartis AG the option either to exclusively license worldwide rights to Elixir's ghrelin antagonist program for diabetes or to acquire the biotech outright. (BioWorld Today) Read More

Santhera Shares Plunge as Ataxia Trial Misses Goal

Strategic vs. Financial Backers: Balance Tricky but Worthwhile

Biomarker Integration Necessary but Complex for Drug Discovery

Clarity, Due Diligence Vital in Cross-Border Alliances

HIV/AIDS Work Facing Cash, Resistance Hurdles and More

Hamburg Wins Senate Confirmation as FDA Chief

Other News To Note

Financings Roundup

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for July 14, 2026.

AI-generated illustration of a neuron with tau protein aggregation

AAIC 2026: Age of amyloid is being joined by time of tau

BioWorld

The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...

Modius Spero wearable neuromodulation device

Neurovalens granted FDA approval for PTSD therapy for US veterans

BioWorld

Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...

News in brief

BioWorld Asia

BioWorld Asia briefs for July 14, 2026

Celia trial: data strong, analysts skeptical

BioWorld

Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...